Etanercept and efalizumab for the treatment of psoriasis: A systematic review

Health Technology Assessment

Volumn 10, Issue 46, 2006, Pages

  Woolacott, N ^a   Hawkins, N ^a   Mason, A ^a   Kainth, A ^a   Khadjesari, Z ^a   Vergel, Y Bravo ^a   Misso, K ^a   Light, K ^a   Chalmers, R ^b   Sculpher, M ^a   Riemsma, R ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; DRUG THERAPY; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; ETRETIN; FUMADERM; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ETHYL ESTER; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHOXSALEN; MONOCLONAL ANTIBODY; PLACEBO; RETINOID DERIVATIVE; SALICYLIC ACID; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLACTIC SHOCK; ANKYLOSING SPONDYLITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BACTEREMIA; BASAL CELL CARCINOMA; BELL PALSY; BIBLIOGRAPHIC DATABASE; BONE MARROW SUPPRESSION; BREAST CANCER; BRONCHITIS; BRONCHOSPASM; CELLULITIS; CHEILITIS; CHILL; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; CLASSIFICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMON COLD; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COUGHING; COXITIS; CYSTITIS; DELAYED HYPERSENSITIVITY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; ECONOMICS; EOSINOPHILIA; EPIGASTRIC PAIN; EVIDENCE BASED MEDICINE; FATIGUE; FECES IMPACTION; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; FOLLICULITIS; FOLLOW UP; FRACTURE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEART INFARCTION; HEMATOLOGIC DISEASE; HERPES; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERSENSITIVITY REACTION; HYPERTENSION; ILEITIS; IMMUNOCYTOMA; INFLUENZA; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE REACTION; INSOMNIA; INTERNET; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOCYTOSIS; LEUKOPENIA; LIGAMENT DISEASE; LIPID BLOOD LEVEL; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG CANCER; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; LYMPHOMA; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; MYALGIA; NATIONAL HEALTH SERVICE; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOMALACIA; OUTCOME ASSESSMENT; PAIN; PATIENT SELECTION; PHARYNGITIS; PHARYNX DISEASE; PHOTOTHERAPY; PNEUMONIA; PRESCRIPTION; PROSPECTIVE PAYMENT; PROSTATE CANCER; PRURITUS; PSOAS ABSCESS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; RESPIRATORY TRACT ALLERGY; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SERUM SICKNESS; SEVERITY OF ILLNESS INDEX; SIDE EFFECT; SINUSITIS; SKIN ATROPHY; SKIN CANCER; SKIN INFECTION; SKIN IRRITATION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; SWEATING; SYNCOPE; SYSTEMATIC REVIEW; TASTE DISORDER; TENDON DISEASE; TERATOGENICITY; THORAX PAIN; THROMBOCYTOPENIA; TIME; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; ULCERATIVE COLITIS; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; UTERINE CERVIX CARCINOMA; VASCULITIS; VERTIGO; VOMITING;

ADVERSE EFFECTS; ANTIBODIES, MONOCLONAL; CLASSIFICATION; COST-BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE; TREATMENT OUTCOME;

EID: 40749144753     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10460     Document Type: Review

References (183)

1. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.
2. McCormick A, Flaming D, Charlton J. Morbidity statistics from general practice: fourth national study - 1991-92. London: HMSO; 1995.
3. Williams HC. Dermatology. In Stevens A, Raftery J, editors. Health care needs assessment: the epidemiologically based needs assessment reviews: second series. Oxford: Radcliffe Medical Press; 1997. pp. 261-348.
4. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533-7.
5. Ameen M. Genetic basis of psoriasis vulgaris and its pharmacogenetic potential. Pharmacogenomics 2003;4:297-308.
6. Granstein RD. New treatments for psoriasis. N Engl J Med 2001; 345:284-7.
7. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-70.
8. Stern RS. Psoriasis. Lancet 1997;350:349-53.
9. Kirby B, Fortune DG, Bhushan M, Chalmers RJG, Griffiths CEM. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000;142:728-32.
10. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135:1490-3.
11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16.
12. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
13. Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000;43:803-8.
14. Rapp SR, Feldman SR, Reboussin D, Fleischer A. Predictors of health-related quality of life in psoriasis and a comparison with other chronic diseases. Qual Life Res 1997;6:705.
15. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales: a measure of the impact of skin diseases. Br J Dermatol 1997; 136:202-6.
16. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. [Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis]. Hautarzt 1999;50:715-22.
17. Mombers FMC, deVries J, DeBakker ESM, Duller P. Severity of psoriasis in relationship to quality of life. Qual Life Res 1997;6:32.
18. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512-18.
19. Kernick D, Cox A, Powell R, Reinhold D, Sawkins J, Warin A. A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis. Br J Gen Pract 2000;50:555-8.
20. Finlay AY, Henley LA. Quality of life and cost-effectiveness of treatment. J Dermatol Treat 1997; 8:28-9.
21. Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001; 145:610-16.
22. Richards HL, Fortune DG, Main CJ, Griffiths CEM. Stigmatization and psoriasis. Br J Dermatol 2003;149:209-11.
23. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-4.
24. Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995;34:700-3.
25. O'Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996;313:919-21.
26. Zug KA, Littenberg B, Baughman RD, Kneeland T, Nease RF, Sumner W, et al. Assessing the preferences of patients with psoriasis a quantitative, utility approach. Arch Dermatol 1995; 131:561-8.
27. Feldman SR, Fleischer AB, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37:564-9.
28. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-44.
29. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796-802.
30. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
31. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5.
32. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-66.
33. Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 2002;3:171-9.
34. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998;17:291-6.
35. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomised clinical trials. Health and Quality of Life Outcomes 2003;1:53. URL: http://www.hqlo.com/content/1/ 1/53
36. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123:751-6.
37. Sampogna F, Sera F, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122:602-7.
38. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996; 10:644-53.
39. de Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002;138:1221-7.
40. Finlay AY, Salek MS, Haney J, Alefacept Clinical Study G. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003;206:307-15.
41. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141:1067-75.
42. Badia X, Mascaro JM, Lozano R, The Cavide Research Group. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999;141:698-702.
43. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997; 136:305-14.
44. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med 1998; 46:1569-85.
45. Stangier U, Ehlers A, Gieler U. Measuring adjustment to chronic skin disorders: validation of a self-report measure. Psychol Assess 2003;15:532-49.
46. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132:942-9.
47. de Tiedra AG, Mercadal J, Badia X, Mascaro JM, Lozano R. A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology. Pharmacoeconomics 1998; 14:405-22.
48. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36:388-94.
49. Fleischer AB, Clark AR, Rapp SR, Reboussin DM, Feldman SR. Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol 1997; 109:170-4.
50. Fortune DG, Main CJ, Osullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137:755-60.
51. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2002; 25:913-27.
52. British Medical Journal. Clinical evidence. London: British Medical Journal; 2004. URL: http://www.clinicalevidence.com/ceweb/conditions/ index.jsp. Accessed November 2004.
53. Department of Health. Hospital episode statistics England: financial year 2002-03. London: Department of Health; 2003. URL: http://www.dh.gov.uk/assetRoot/04/06/74/03/04067403.pdf. Accessed 12 December 2004.
54. Department of Health. Prescription cost analysis, England 2003: prescription items dispensed in the community in England and listed alphabetically within chemical entity by therapeutic class. London: Department of Health; 2004. URL: http://www.dh.gov.uk/ PublicationsAndStatistics/Publications/PublicationsStatistics/ PublicationsStatisticsArticle/fs/en?CONTENT_ID=4081720&chk=kVOup3. Accessed 17 December 2004.
55. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol in the treatment of mild to moderate plaque psoriasis. Pharmacoeconomics 2000;18:469-76.
56. Cockayne SE, Cork MJ, Gawkrodger DJ. Treatment of psoriasis: day care vs. inpatient therapy. Br J Dermatol 1999;140:375-6.
57. Davies L, Levell N, Munro CS, Cork MJ. Short course cyclosporin therapy for psoriasis: benefits, risks and costs. Br J Dermatol 1997; 137 Suppl 50: 53.
58. Cork M. Economic considerations in the treatment of psoriasis. Dermatol Pract 1993;1:16-20.
59. Sarkany R. Access to care. London: British Association of Dermatologists; 2001. URL: http://www.bad.org.uk/patients/access/. Accessed 17 December 2004.
60. Shum KW, Lawton S, Williams HC, Docherty G, Jones J. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 1: audit of service structure. Br J Dermatol 1999;141:430-7.
61. Gniadecki R, Zachariae C, Calverley M. Trends and developments in the pharmacological treatment of psoriasis. Acta Derm Venereol 2002; 82:401-10.
62. Pariser DM. Management of moderate to severe plaque psoriasis with biologic therapy. Manag Care 2003;12:36-44.
63. Wyeth Pharmaceuticals. Enbrel [summary of product characteristics]. Electronic Medicines Compendium; 2004. URL: http://emc.medicines.org.uk/ emc/assets/c/html/displaydoc.asp?documentid=3343. Accessed 15 December 2004.
64. Serono Ltd. Raptiva 100 mg/ml [summary of product characteristics]. Electronic Medicines Compendium; 2004.URL: http://emc.medicines.org.uk/ emc/assets/c/html/displaydoc.asp?documentid=15279. Accessed 15 December 2004.
65. British Medical Association. British national formulary, No. 48. London: British Medical Association; 2004. URL: http://bnf.org.
66. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4(40).
67. Whitehead A. Meta-analysis of controlled clinical trials. Chichester: Wiley; 2002.
68. Higgins JPT, Whitehead J. Borrowing strength from external trials in meta-analysis. Stat Med 1996;15:2733-49.
69. Wyeth Pharmaceuticals. Enbrel and psoriasis: an appraisal submission for the National Institute for Clinical Excellence [industry submission]. Maidenhead: Wyeth Pharmaceuticals; 2004.
70. Serono Ltd. Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis. Feltham: Serono Ltd; 2004.
71. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
72. Elewski BE, Boh E, Papp K, Zitnik R. Efficacy and safety of etanercept in patients with psoriasis: results of a global phase 3 study. J Am Acad Dermatol 2004;50:159.
73. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32.
74. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
75. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073-80.
76. ACD2058g. Phase III, randomised double blind placebo-controlled study evaluating 12 weeks of therapy with XOMA1 efalizumab administered subcutaneously (SC), followed by either continued treatment for an additional 12 weeks or retreatment for 12 weeks following relapse. In Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis [industry submission]. Feltham: Serono Ltd; 2004.
77. ACD2600g. Phase IIIb, randomised, double-blind, parallel group, placebo-controlled, multicentre study evaluating 12 weeks therapy with subcutaneously administered Genentech efalizumab in adults with moderate to severe psoriasis who are candidates for systemic therapy. In Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis [industry submission]. Feltham: Serono Ltd; 2004.
78. IMP24011. Phase III, randomised, double blind, placebo-controlled, multicentre study evaluating 12 weeks subcutaneous therapy with Genentech efalizumab in patients with moderate to severe psoriasis who are candidates for systemic therapy. In Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis [industry submission]. Feltham: Serono Ltd; 2004.
79. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45:665-74.
80. United States Pharmacopeial Convention. USPDI, vol 1: drug information for the health care professional. Rockville, MD: United States Pharmacopeial Convention: 2004.
81. Sweetman SC, editor. Martindale: the complete drug reference [CD-ROM]. London: Pharmaceutical Press; 2002.
82. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Saf 2004;27:307-24.
83. Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S203-8.
84. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65:33-8.
85. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 2003;48:3013-22.
86. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
87. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002:20 (6 Suppl 28):s152.
88. Keystone EC. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis 2003:62 Suppl 2:34-6.
89. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002;62:2493-537.
90. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29:185-202.
91. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003;49:S105-11.
92. Davis JC, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - a randomized, controlled trial. Arthritis Rheum 2003;48: 3230-6.
93. Klareskog L, van der Heijde D, De Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomised controlled trial. Lancet 2004; 363:675-81.
94. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264-72.
95. Gottlieb A, Hamilton TK, Caro I, Chastain R, Rundle AC, Gordon KB. Efficacy and safety outcomes of extended efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: an update [poster]. American Academy of Dermatology; 2004.
96. Geborek P, Crnkic M, Petersson IF, Saxne T, South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002:61:793-8.
97. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999:130:478-86.
98. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000:343:1586-93.
99. Willis RF, Pedersen R. A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis). J Rheumatol 2001; 28:W104.
100. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21.
101. Tam JW, Lee GJ, Song JC. Efalizumab: a new biologic therapy for the control of chronic plaque psoriasis. Formulary 2004; 39:20-39.
102. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49:S98-104.
103. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84.
104. Guenther L, Wexler D. Inducing remission of severe psoriasis with low dose cyclosporin A. Can J Dermatol 1991;3:163-7.
105. Meffert H, Brautigam M, Farber L, Weidinger G. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997;77:137-41.
106. van Joost T, Bos JD, Heule F, Meinardi MM. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988; 118:183-90.
107. Sandhu K, Kaur I, Kumar B, Saraswat A. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003;30:458-63.
108. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658-65.
109. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988;18:655-62.
110. Lassus A, Geiger JM, Nyblom M, Virrankoski T, Kaartamaa M, Ingervo L. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol 1987;117:333-41.
111. Caca-Biljanovska NG, V'Lckova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 2002;43:707-12.
112. Saurat JH, Geiger JM, Amblard P, Beani JC, Boulanger A, Claudy A. et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177:218-24.
113. Sommerburg C, Kietxmann H, Eichelberg D, Goos M, Heese A, Holze A, et al. Acitretin in combination with PUVA: a randomised double-blind placebo controlled study in severe psoriasis. J Eur Acad Dermatol Venereol 1993;2:303-17.
114. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682-4.
115. Dogan B, Taskapan O, Cekmen S. Karabudak O, Harmanyeri Y. PUVA-alone, bath-PUVA, and re-PUVA in the treatment of psoriasis: a clinical comparison. Gulhane Med J 1999;41:439-42.
116. van de Kerkhof PCM, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, et al. The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis. Br J Dermatol 1998;1998:84-9.
117. Rim JH, Park JY, Choe YB, Youn JI. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy. Am J Clin Dermatol 2003;4:507-10.
118. van Weelden H, Baart de la Faille H, Young E, van der Leun JC. Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol 1990; 70:212-15.
119. Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41:728-32.
120. Markham T, Rogers S, Collins P. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003;139:325-8.
121. Dawe RS, Cameron H, Yule S, Man I, Wainwright NJ, Ibbotson SH, et al. A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemotherapy for psoriasis. Br J Dermatol 2003;148:1194-204.
122. Storbeck K, Holzle E, Schurer N, Lehmann P, Plewig G. Narrow-band UVB (311 nm) versus conventional broad-band UVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 1993; 28:227-31.
123. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
124. Gottlieb A, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42.
125. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994;30:977-81.
126. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 1990; 22:311-12.
127. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-16.
128. Roenigk HH, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38:478-85.
129. Schering-Plough Ltd. Remicade [summary of product characteristics]. Electronic Medicines Compendium; 2004. URL: http://emc.medicines.org.uk/emc/assets/c/html/ displaydoc.asp?documentid=3236. Accessed 15 December 2004.
130. Dukes M, Aronson J. Meyler's side effects of drugs: an encyclopedia of adverse reactions and interactions. 14 ed. Amsterdam: Elsevier; 2000.
131. Jones A. Applied econometrics for health economists: a practical guide. London: Office of Health Economics; 2001.
132. Greene WH. Econometric analysis. 4th ed. London: Prentice-Hall International; 2000.
133. Spiegelhalter DJ, Thomas A, Best N, Lunn D. WinBUGS user manual: version 1.4. Cambridge: MRC Biostatistics Unit; 2001.
134. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997.
135. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003;4:1525-33.
136. McHugh N, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, et al. BSR guideline for anti-TNFa therapy in psoriatic arthritis. London: British Society for Rheumatology; 2004. URL: https://www.msecportal.org/portal/editorial/PublicPages/bsr/536883013/ FinalPsoriaticArthritisGuideline.pdf. Accessed 14 December 2004.
137. Cooper NJ, Sutton AJ, Abrams KR, Turner D, Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ 2004;13:203-26.
138. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 69:3-17.
139. Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150:11-23.
140. Wyeth Research. Multicenter dose-ranging study of the safety and efficacy of Enbrel in psoriasis: withdrawal and re-treatment final report: protocol no.: 20021639 [industry submission]. Philadelphia, PA: Wyeth Research; 2003.
141. National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a Technology Appraisal. London: NICE; 2001.
142. Royal College of Nursing Rheumatology Biologics Working Party, Arthritis and Musculoskeletal Alliance, Royal College of Nursing Paediatric Rheumatology Specialist Nurses Group. Assessing, managing and monitoring biologic therapies for inflammatory arthritis: guidance for rheumatology practitioners. An advisory document. London: Royal College of Nursing; 2003. URL: http://www.rcn.org.uk/publications/pdf/ inflammatory-arthritis.pdf. Accessed 14 December 2003.
143. Chalmers RJG, Kirby B, Smith A, Burrows P, Little R, Horan M, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring psoriasis patients receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-50.
144. Curtis L, Netten A. Unit costs of health and social care 2004. Canterbury: The University of Kent, Personal Social Services Research Unit, 2004. Available from: http://www.pssru.ac.uk/
145. Department of Health. NHS reference costs 2003 and national tariff 2004 ('payment by results core tools 2004'). London: Department of Health; 2004. URL: http://www.dh.gov.uk/PublicationsAndStatistics/ Publications/PublicationsPolicyAndGuidance/ PublicationsPolicyAndGuidanceArticle/fs/ en?CONTENT_ID=4070195&chk=UzhHA3. Accessed 23 November 2004.
146. Wyeth Research. Phase 3 study of the safety and efficacy of Enbrel in psoriasis: final 12-week report: protocol no. 20021642. Philadelphia, PA: Wyeth Research; 2003.
147. Wyeth Research. Phase 3 study of the safety and efficacy of Enbrel in psoriasis: open-label final report: protocol no. 20021642. Philadelphia, PA: Wyeth Research; 2003.
148. Gordon K, Korman N, Frankel E. Efficacy of Etanercept in an integrated multi-study database of patients with psoriasis [industry submission]. Poster 8. 62nd Annual Meeting of American Academy of Dermatology, 6-11 February 2004; Washington, DC.
149. Gottlieb AB, Coffe B, Veith J. Safety of etanercept in an integrated multi-study database of patients with psoriasis. Poster 161. 62nd Annual Meeting of American Academy of Dermatology, 6-11 February 2004; Philadelphia, PA.
150. Wyeth Research. Double-blind, placebo-controlled, phase 2 study of Etanercept (ENBREL®) in the treatment of psoriasis: final report: protocol no. 016.0032 [industry submission]. Philadelphia, PA: Wyeth Research; 2003.
151. Gaspari A, Gottlieb AB, Kang S, Gordon K, Feng S. Enbrel improves the clinical and pathologic features of psoriasis. J Invest Dermatol 2002;119:236.
152. Gottlieb A, Matheson RT, Lowe NJ. Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol 2002;119:234.
153. Wyeth Research. Multicenter dose-ranging study of the safety and efficacy of Enbrel in psoriasis: withdrawal and re-treatment: final report: protocol no. 20021639 [industry submission]. Philadelphia, PA: Wyeth Research; 2003.
154. Krueger GG, Lebwohl M, Wang A, Zitnik R. Continuance on Etanercept after early incomplete response in patients with psoriasis. Poster. 62nd Annual Meeting of American Academy of Dermatology, 6-11 February 2004; Washington, DC.
155. Gottlieb AB, Gordon K, Wang K, Wang A, Zitnik R. Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response. J Am Acad Dermatol 2004; 50(3 Suppl 1):146.
156. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004;3:27-38.
157. Hamilton T, Powers J, Carey W. Efficacy and safety of efalizumab (anti-CD11a) in subjects with moderate to severe plaque psoriasis. Presented at the 61st Annual Meeting of the American Academy of Dermatology, 21-26 March 2003, San Francisco, CA.
158. ACD2390g. Phase III, randomised, placebo-controlled, double blind study evaluating 12 weeks of therapy with SC administered Genentech efalizumab. In Clinical and cost effectiveness of efalizumab
159. Gordon K, Leonardi C, Tyring S, Gottlieb A, Walicke P, Dummer W. Efalizumab (Anti-CD11a) is safe and effective in the treatment of psoriasis: pooled results of the 12-week first treatment period from 2 phase III trials. J Invest Dermatol 2002;119:242.
160. ACD2059g. Phase III, randomised, placebo-controlled, double blind study evaluating 12 weeks with SC administered efalizumab (approx 75% XOMA1 and 25% Genentech1), followed by a 2nd placebo-controlled period with either continued active treatment or placebo for 12 weeks. In Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasis [industry submission]. Feltham: Serono Ltd; 2004.
161. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443-50.
162. Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 2003;21 Suppl 31:S195-7.
163. Wyeth Research. Double-blind, randomized, placebo-controlled phase 3 study of etanercept (ENBREL) in the treatment of psoriatic arthritis (PsA) and psoriasis: final report: protocol 016.0030 [industry submission]. Philadelphia, PA: Wyeth Research; 2001.
164. Wyeth Research. Double-blind, randomized, placebo-controlled phase 3 study of etanercept (ENBREL) in the treatment of psoriatic arthritis (PsA) and psoriasis: radiographic results: protocol no. 016.0030 [industry submission]. Philadelphia, PA: Wyeth Research; 2003.
165. Wyeth Pharmaceuticals. Marketing authorisation application for Enbrel: expert report on the clinical documentation [industry submission]. Philadelphia, PA: Wyeth Pharmaceuticals; 2001.
166. Ory P, Sharp JT, Salonen D, Rubenstein J, Mease PJ, Kivitiz A, et al. Etanercept (ENBREL (R)) inhibits radiographic progression in patients with psoriatic arthritis. Arthritis Rheum 2002; 46: S196.
167. Wajdula J, Pedersen R, Sanda M. A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis). Arthritis Rheum 2000; 43:974.
168. Gottlieb A, Blacker K, Duvic M. Efficacy and safety of efalizumab (anti-CD11a) long-term treatment: preliminary findings from an open-label trial [poster 11]. Presented at the 61st Annual Meeting of the American Academy of Dermatology, 21-26 March 2003, San Francisco, CA.
169. Gottlieb A, Menter A, Duvic M. Induction and maintenance treatment during a 12 month trial in patients with moderate to severe plaque psoriasis: preliminary findings [poster 546]. Presented at the 60th Annual Meeting of the American Academy of Dermatology, 22-27 February 2002, New Orleans, LA.
170. ACD2243g. Ongoing phase III open-label study evaluating 12 weeks of therapy with Genentech efalizumab (in combination with topical corticosteroids for days 56-84) and up to 132 additional weeks of therapy. In Clinical and cost effectiveness of efalizumab (Raptiva) for moderate to severe psoriasic [industry submission]. Feltham: Serono Ltd; 2004.
171. Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research: Arthritis Advisory Committee. Safety update on TNF-α antagonists; infliximab and etanercept. Rockville, MD: US Food and Drug Administration. URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3779b20_01_cber_safety%20_revision2.pdf. Accessed 10 October 2004.
172. Nieboer C, de Hoop D, van Loenen AC, Langendijk PN, van Dijk E. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989; 20:601-8.
173. Nieboer C, de Hoop D, Langendijk PN, van Loenen AC, Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990;181:33-7.
174. Engst R, Huber J. [Results of cyclosporin treatment of severe, chronic psoriasis vulgaris]. Hautarzt 1989;40:486-9.
175. Kingston TP, Matt LH, Lowe NJ. Etretin therapy for severe psoriasis. Evaluation of initial clinical responses. Arch Dermatol 1987; 123:55-8.
176. Madhok R, Muller SA, Dicken CH. Treatment of psoriasis with etretin: a preliminary report. Mayo Clin Proc 1987;62:1084-9.
177. Olsen EA, Weed WW, Meyer CJ, Cobo LM. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989;21:681-6.
178. Williams R. PUVA therapy vs Goeckerman therapy in psoriasis: a pilot study. Physiother Can 1985; 37:361-6.
179. Leavell UW Jr, Yarbro JW. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 1970; 102:144-50.
180. Ellis C, Gorsulowsky D, Hamilton T, Billings J, Brown M, Headington J, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-16.
181. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc B 2000;64: 583-640.
182. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
183. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42: 326-35.